Evidence map›Paper›PMID 37347247›Full record

Trial reportGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2023

Optical coherence tomography angiography-guided vs indocyanine green angiography-guided half-dose photodynamic therapy for acute central serous chorioretinopathy: 6-month randomized trial results.

Siying Li, Linqi Zhang, Jiyang Tang, Zongyi Wang, Jinfeng Qu, Mingwei Zhao

Abstract readRandomized Controlled TrialComparative Study
In one paragraph

Trial report in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Interventions for central serous chorioretinopathy: a network meta-analysis.The Cochrane database of systematic reviews · 2025
    Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Siying LiDepartment of Ophthalmology, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University People's Hospital; Eye Diseases and Optometry Institute; Peking University Health Science Center, No. 11 South Avenue of XiZhiMen, 100044, Xi Cheng District, Beijing, People's Republic of China.
Linqi ZhangDepartment of Ophthalmology, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University People's Hospital; Eye Diseases and Optometry Institute; Peking University Health Science Center, No. 11 South Avenue of XiZhiMen, 100044, Xi Cheng District, Beijing, People's Republic of China.
Jiyang TangDepartment of Ophthalmology, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University People's Hospital; Eye Diseases and Optometry Institute; Peking University Health Science Center, No. 11 South Avenue of XiZhiMen, 100044, Xi Cheng District, Beijing, People's Republic of China.
Zongyi WangDepartment of Ophthalmology, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University People's Hospital; Eye Diseases and Optometry Institute; Peking University Health Science Center, No. 11 South Avenue of XiZhiMen, 100044, Xi Cheng District, Beijing, People's Republic of China.
Jinfeng QuDepartment of Ophthalmology, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University People's Hospital; Eye Diseases and Optometry Institute; Peking University Health Science Center, No. 11 South Avenue of XiZhiMen, 100044, Xi Cheng District, Beijing, People's Republic of China. jinfeng_qupku@163.com.ORCID http://orcid.org/0000-0001-9975-1602
Mingwei ZhaoDepartment of Ophthalmology, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University People's Hospital; Eye Diseases and Optometry Institute; Peking University Health Science Center, No. 11 South Avenue of XiZhiMen, 100044, Xi Cheng District, Beijing, People's Republic of China. zhaomingweipku@163.com.

Funding

Beijing Natural Science Foundation 7232192National Key R&D Program of China 2020YFC2008200
6 · The paper itself

Abstract

purposeThis study aimed to compare the anatomic and functional results of optical coherence tomography angiography (OCTA)-guided half-dose photodynamic therapy (PDT) versus indocyanine green angiography (ICGA)-guided PDT in eyes with acute central serous chorioretinopathy (CSC).

methodsOne hundred and thirty-one eyes of 131 patients with acute central serous chorioretinopathy (CSC) were recruited, and randomly assigned to the OCTA-guided group and ICGA-guided group. The primary outcome measures were the rates of complete subretinal fluid (SRF) resolution at 1 month, 3 months, and 6 months. The secondary outcomes included best-corrected visual acuity (BCVA), central retinal thickness (CRT), choroidal capillary flow deficit density at each scheduled visit, and recurrence rate of SRF at 3 months and 6 months.

resultsThere were 110 eyes that finished the follow-up, with 56 eyes in the OCTA-guided group and 54 eyes in the ICGA guided group. OCTA-guided PDT was demonstrated to be noninferior to ICGA-guided PDT for SRF resolution rate at 1 months and 6 months (P = 0.021 and P = 0.037), but not at 3 months for acute CSC (P = 0.247). The average CRT of the ICGA-guided group was significantly lower than that of the OCTA-guided group at 3-month visit (P = 0.046), but no significant difference was found between them at the 1-month and 6-month visits (P = 0.891 and 0.527). There was no significant difference between the two groups for BCVA (P = 0.359, 0.700, and 0.143, respectively) and the deficit area on CC (P = 0.537, 0.744,and 0.604, respectively) at 1, 3, and 6 months.

conclusionOCTA may replace ICGA to guide PDT for the treatment of acute CSC and their follow-up.

Indexed as

Central Serous ChorioretinopathyFluorescein AngiographyIndocyanine GreenPhotochemotherapyTomography, Optical CoherenceVerteporfinVisual AcuityAcute DiseaseAdultChoroidColoring AgentsDose-Response Relationship, DrugFemaleFollow-Up StudiesFundus OculiHumansColoring AgentsIndocyanine GreenPhotosensitizing AgentsVerteporfinAcute CSCICGA-guidedOCTA-guidedPDT

Identifiers

PMID37347247
PMCPMC10587313

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.